Lack of pharmacokinetic interaction between derazantinib and naringin in rats
Sign Up to like & getrecommendations! Published in 2023 at "Pharmaceutical Biology"
DOI: 10.1080/13880209.2023.2185641
Abstract: Abstract Context Derazantinib—an orally bioavailable, ATP competitive, multikinase inhibitor—has strong activity against fibroblast growth factor receptors (FGFR)2, FGFR1, and FGFR3 kinases. It has preliminary antitumor activity in patients with unresectable or metastatic FGFR2 fusion-positive intrahepatic… read more here.
Keywords: derazantinib; derazantinib naringin; lack pharmacokinetic; naringin ... See more keywords